EFB Dengue Wiki — Master Index
Last updated: 2026-06-29 | Sources: 22 | Total pages: 107
Sources (22)
| Page | Year | Journal | Disease Context |
|---|---|---|---|
| Morra2018 - Defining Warning Signs and Severe Dengue | 2018 | Rev Med Virol | Clinical classification (LANDMARK): PRISMA systematic review of how 44 WHO-2009 studies operationally define warning signs / severe-dengue signs; only 2 of 16 signs (liver enlargement, liver involvement = AST/ALT >1000) had consensus definitions — both WHO-2009-predefined; “shock” defined via 23 distinct parameter-combinations; hematocrit/platelet/respiratory-rate cutoffs all divergent. Within-scheme definitional heterogeneity compounds Narvaez2011’s between-scheme heterogeneity; contains Narvaez2011 as its ref #40. No own diagnostic-accuracy data (73.0% vs 93.4% specificity borrowed from Macedo et al) |
| Narvaez2011 - Evaluating WHO Dengue Severity Classifications | 2011 | PLoS Negl Trop Dis | Clinical classification (LANDMARK): evaluates WHO-1997 (DF/DHF/DSS) vs WHO-2009 (Dengue±Warning Signs / Severe Dengue) against clinical intervention level; n=544 pediatric Nicaragua; Severe Dengue sens/spec 92.1%/78.5% vs DHF/DSS 39.0%/75.5%; schemes agree only κ=0.25; DENV-2→DHF/DSS association lost under the revised scheme |
| Lamprinou2026 - ABCs and DN B Cells | 2026 | Front Aging | Opinion (ABC↔DN identity): ABC is a heterogeneous superset (CD27⁺ + IgD⁺ + predominantly IgD⁻CD27⁻); only its IgD⁻CD27⁻ subset ≈ DN2; DN1–DN4 taxonomy (adds DN4); IL-21→CD11c, IFN-γ→T-bet; no dengue data; self-cited framework |
| Wrammert2012 - Plasmablast Responses in Acute Dengue | 2012 | J Virol | Dengue (FOUNDATIONAL: first systematic PB characterisation; 47% of B cells; >1,000-fold expansion; day 6–7 peak; ≥70% DENV-specific IgG; cross-serotype reactive; no severity correlation [confounded]) |
| Parameswaran2013 - Convergent Antibody Signatures in Dengue | 2013 | Cell Host Microbe | Dengue (FIRST BCR REPERTOIRE: convergent CDR3s across patients; 4.4–6.9% V mutation = memory-derived; higher clonality in secondary; convergent evolution from multiple V genes; n=60) |
| GarciaBates2013 - Plasmablast Response and Dengue Severity | 2013 | J Immunol | Dengue (LANDMARK: severity-stratified plasmablast data; 46% mean/87% peak in 2° DFC; >70% DENV-specific; serotype cross-reactive; plasmablast-PRNT₅₀ disconnect; B cell apoptosis) |
| Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue | 2025 | Cell Reports | Dengue (LANDMARK: first EF B cell evidence; Tph→IL-21→memory B cell→plasmablast; CD21⁻CD11c⁺ DN expansion; severity association; neutralizing Ab paradox) |
| Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool | 2016 | EBioMedicine | Dengue (CLONAL DISCONNECT: PBs and DENV-binding MBCs clonally unrelated; PBs 85% E-specific, MBCs 56% complex epitope; VH4-34 enrichment in PBs; IgM-dominant DENV-binding MBCs; n=12) |
| Priyamvada2016 - Cross-Reactive Memory Plasmablasts in Secondary Dengue | 2016 | J Virol | Dengue (OAS + ADE: 53 mAbs from sorted 2° DHF PBs; 70% E-specific, all cross-reactive; 45/53 ADE-competent; OAS in 2/4 patients — DENV1 neutralised over infecting DENV2; mean 18.1 VH mutations = memory origin; n=4 2° DHF) |
| GodoyLozano2016 - Lower IgG SHM Rates in Acute Dengue | 2016 | Genome Medicine | Dengue (LANDMARK: first direct SHM measurement in dengue IgG plasmablasts; paradoxically low SHM in acute phase; lower in secondary than primary; lower in DWS+ than DWS−; IGHV1-2/1-69 bias; convergent CDRH3s at 52% prevalence; GC-independent pathway proposed; n=19) |
| Singh2026 - DENV-Specific Memory B Cell Subsets | 2026 | bioRxiv | Dengue (DENV-specific MBC subsets; primary vs secondary; longitudinal to 18M) |
| Scharer2019 - Epigenetic Programming in SLE B Cells | 2019 | Nat Immunol | SLE (multi-omic epigenetics; RRBS + ATAC-seq + RNA-seq; T-BET/AP-1/EGR/ATF3 programmes) |
| Sanz2025 - Human Atypical B Cells Overview | 2025 | Immunol Rev | Review (AtB nomenclature, DN classification, cross-disease context) |
| Woodruff2020 - EF B Cell Responses in COVID-19 | 2020 | Nat Immunol | COVID-19 (EF pathway in acute viral infection; DN2/aN/ASC expansion; neutralizing Ab paradox) |
| Jenks2018 - DN2 B Cells and EF Pathway in SLE | 2018 | Immunity | SLE (DN2 B cells, complete EF pathway, TLR7) |
| Tipton2015 - ASC Diversity and Origin in SLE | 2015 | Nat Immunol | SLE (ASC diversity, EF origin, acN cells) |
| Wei2007 - DN Memory B Cells in SLE | 2007 | J Immunol | SLE (comparative immunology baseline) |
| William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice | 2002 | Science | SLE/Autoimmunity (LANDMARK: first direct demonstration of SHM outside GCs; ~0.3 mut/gene/gen at T zone–red pulp border; genealogical trees; FDC-absent, DC-rich EF niche; TLR9 co-stimulation; tolerance escape; 585 citations) |
| Bhattacharya2016 - Memory B Cell Subset Selection in Secondary Dengue | 2016 | EBioMedicine | Commentary on Appanna2016: isotype-fate segregation (IgM→GC, IgG→PB); PB analysis insufficient as DENV immunity correlate; MBC subset recruitment |
| Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection | 2021 | Cell Reports | Malaria/Vaccination (LANDMARK: scRNA-seq + CITE-seq defines “alternative lineage” (atBC1-3 + MBC1) vs “classical lineage”; T-bet/CD11c/FCRL5 defining markers; CD21⁻CD27⁻ gating captures only 44.7% of transcriptomic atBCs; ~20% of B cells in healthy donors; no PC genes in atBCs — challenges EF pre-PB model; MBC1 = quiescent alternative memory; IgG3 enrichment; n=4 10x Chromium + n=11 Smart-seq2) |
| Kaneko2020 - GC Loss and TFH Block in COVID-19 | 2020 | Cell | COVID-19 (LANDMARK TISSUE: GC loss + TFH block in post-mortem LN/spleen; Bcl-6⁺ GC B cell depletion; AID⁺ preservation; TNF-α-mediated TFH block; DN/aN/PB expansion with RBD specificity; tissue-level foundation for EF dominance model) |
| Anolik2004 - Rituximab and B Cell Abnormalities in SLE | 2004 | Arthritis Rheum | SLE (B cell homeostasis; rituximab trial) |
Entities (48)
B Cell Subsets
- Atypical B Cell — umbrella / hub for the atypical / age-associated B cell cluster (the wiki’s cellular spine); synonymy map AtB/ABC/T-bet⁺/CD11c⁺/DN/alternative-lineage → precise sub-populations; foregrounds the Sanz2025 nomenclature debate; routes to the DN sub-pages without restating them (sources: 7)
- Age-Associated B Cell — murine-origin CD19⁺CD21⁻CD23⁻T-bet⁺CD11c⁺ population; heterogeneous superset (CD27⁺ + IgD⁺ + predominantly IgD⁻CD27⁻); only its IgD⁻CD27⁻ subset ≈ DN2; TLR7/9+IFN-γ/IL-21 driven; GC-experienced origin debated; therapeutics portfolio (sources: 3)
- Double-Negative B Cell — IgD⁻CD27⁻ memory B cells; DN1/DN2/DN3 (+DN4) subdivision; CD21⁻CD11c⁺ EF phenotype now confirmed in dengue; tissue-level DN in COVID-19 follicular + EF sites; alternative lineage framework recontextualises DN (sources: 13)
- DN2 B Cell — IgD⁻CD27⁻CXCR5⁻CD21⁻CD11c⁺CD19^hi; EF pre-plasmablast; human counterpart of murine ABC; first dengue evidence from Ansari2025; RBD-specific in COVID-19; alternative lineage framework (Sutton2021) (sources: 8)
- DN3 B Cell — IgD⁻CD27⁻CXCR5⁻CD21⁻CD11c⁻T-bet⁻; pre-plasmablast; proliferation+UPR signature; COVID-19/IgG4-RD/SLE-activity (sources: 4)
- Plasmablast — CD20⁻CD38⁺⁺CD27⁺Ki67⁺CD71⁺CXCR3⁺; tissue-level IgG⁺ PBs in follicular + EF sites (Kaneko2020); 47% of B cells (Wrammert2012); 46% mean/87% peak in severe 2° dengue; plasmablast–neutralization disconnect; high SHM + OAS + near-universal ADE; atBCs do NOT upregulate PC genes (Sutton2021) (sources: 17)
- Activated Naive B Cell — CD19^hi, MTG⁺/CD11c⁺, CD24⁻, CD21⁻; EF ASC precursor; RBD-specific in COVID-19; epigenetically closer to DN2 in SLE (sources: 6)
- Switched Memory B Cell — IgD⁻CD27⁺ GC-derived memory; the germinal-center comparator to DN/DN2 (side-by-side in the IgD/CD27 quadrant, differ only by CD27); resting (CD21⁺) vs activated (CD21⁻) split; sM↔DN boundary blurred by CD27 shedding; recall reservoir for the IgG⁺ PB burst in 2° dengue (sources: 11)
- Memory B Cell — see Concepts (foundational concept page)
T Cell Subsets
- Peripheral Helper T Cell — CXCR5⁻PD-1⁺ CD4⁺; ~75% of activated CD4⁺ T cells in dengue; IL-21⁺ helper vs GZMB⁺ cytotoxic subclusters; drives memory B cell→PB differentiation (sources: 1)
Surface Markers & Receptors
- CD19 — pan-B cell marker; CD19^hi marks DN2 and acN cells; CD19^lo marks plasmablasts (sources: 14)
- CD20 — B cell marker lost on plasmablasts; rituximab target reduces ABC/DN in SLE; PB gating in dengue (sources: 8)
- CD21 — complement receptor; CD21⁻ defines EF populations; CD21⁻CD11c⁺ B cells expanded in dengue; progressive CD21 loss along alternative lineage pseudotime (sources: 8)
- CD23 — low-affinity IgE receptor; CD23⁻ marks acN cells; disease-activity proxy (sources: 1)
- CD24 — CD24⁻ shared by acN and DN2 cells; discriminates from transitional B cells (sources: 4)
- CD27 — canonical memory marker; obsolete as sole memory marker; CD27 can be modulated; some ABCs are CD27⁺ (only IgD⁻CD27⁻ ABCs map to DN); CD27⁻ does not cleanly separate alternative from classical lineage (sources: 15)
- CD38 — activation/differentiation marker; CD38^hi on plasmablasts; CD38⁺HLA-DR⁺ on activated T cells (sources: 14)
- CD10 — transitional/GC marker; CD10⁻ on DN cells and acN cells; mature B cell gate in dengue (sources: 4)
- CD11c — ITGAX integrin; defining marker of DN2/aNAV/ABC; IL-21-induced; CD11c⁺ EF B cells confirmed in dengue; CD11c⁺ DCs at EF sites (William2002); best single surface marker for alternative lineage by CITE-seq (sources: 9)
- CD138 — plasmablast maturation marker; CD138⁺ enriched in severe COVID-19 ASCs; first dengue panel inclusion (sources: 4)
- CD40L — CD154; T-B costimulation; inhibits EF pathway from naive cells; expressed on Tph in dengue (sources: 2)
- CD71 — transferrin receptor; proliferation marker on dengue plasmablasts (sources: 1)
- ICOS — co-stimulatory receptor; CD4⁺ICOS⁺ TFH diminished in COVID-19 tissue (sources: 1)
- CXCR5 — follicle-homing receptor; top axis of DN1–DN4 classification (DN1/DN4 CXCR5⁺ vs DN2/DN3 CXCR5⁻); absent on DN2 B cells and Tph T cells; Bcl-6⁺CXCR5⁺ GC-TFH absent in COVID-19; CXCL13 elevated in dengue (sources: 7)
- CXCR3 — IFN-γ-driven tissue homing; CXCR3⁺ on dengue plasmablasts and COVID-19 EF populations; measured by CITE-seq on alternative lineage (sources: 3)
- FCRL5 — Fc receptor-like 5; expressed on DN2/aNAV; therapeutic target candidate; defining marker of alternative lineage (sources: 3)
- FcRH4 — inhibitory Fc receptor homolog; absent on circulating DN cells and DN2 (sources: 3)
- SLAMF7 — CD319; expressed on DN2/aNAV/PC; therapeutic target (approved for myeloma) (sources: 2)
- IgD — surface immunoglobulin; retained on acN cells; lost at DN2 transition; used for DN gating; IgD⁺ ABCs are antigen-experienced (SHM⁺), not naive (sources: 11)
- IgG — predominant switched isotype; DENV-specific IgG massive but non-neutralizing; anti-NS1/anti-prM elevated in severe dengue; PB IgG 85% E-specific and more neutralizing; near-universal ADE; OAS bias; IgG⁺ MBCs predisposed to PB fate; predominant ABC isotype; IgG3 enriched in alternative lineage (sources: 16)
- IgM — unswitched isotype; balanced with IgG1/IgA1 in COVID-19 ASC; ongoing CSR to switched isotypes; IgM-dominant in DENV-binding MBCs; IgM⁺ MBCs predisposed to GC re-initiation (sources: 8)
- IgA — mucosal isotype; IgA1 in COVID-19 ASC repertoire; anti-RBD IgA elevated in severe COVID; one of two dominant ABC switched isotypes (sources: 8)
- B220 — CD45R isoform; heterogeneous in memory B cells (sources: 1)
Transcription Factors & Signalling
- Bcl-6 — GC master TF; Bcl-6⁺ GC B cells and GC-TFH strikingly absent in COVID-19; DN1 Bcl-6-pathway associated; link to GC failure→EF dominance (sources: 3)
- T-bet — TBX21; defining TF of ABC; IFN-γ-induced; highest in DN2/aNAV; only DN subset (DN2) highly T-bet⁺; T-BET motifs top enriched in DN2 chromatin; TH1 CD4⁺ T-bet⁺ expansion in COVID-19 tissue; not stained in dengue; defines alternative lineage transcriptomically (sources: 8)
- ZEB2 — primary driver of ABC formation; represses Mef2b (GC TF); cooperates with T-bet (sources: 2)
- ATF3 — stress-response TF; key SLE DN2-specific regulator; 98 target genes (sources: 1)
- EGR — EGR1-4 family; EGR4 highest PageRank in SLE network (sources: 1)
- PD-1 — PDCD1; ~60% PD-1⁺ on DN2 B cells; defining marker of Tph T cells in dengue (sources: 2)
- IRF4 — PC differentiation TF; high IRF4/low IRF8 ratio in DN2; NOT upregulated in atBC clusters (Sutton2021) (sources: 5)
- BLIMP-1 — PRDM1-encoded; elevated in DN2/aNAV; progressive demethylation; NOT upregulated in atBC clusters (Sutton2021) (sources: 5)
- BACH2 — terminal differentiation repressor; absent in DN2/aNAV (sources: 2)
- TRAF5 — negative TLR regulator; uniquely low in DN2/aNAV (sources: 2)
- TLR7 — ssRNA sensor; TLR7 GoF causes SLE; X-linked (female bias); ABCs hyper-responsive to TLR7+TLR9; monogenic + indirect mutations drive ABC/DN2; TLR9 EF precedent (William2002) (sources: 5)
- HOPX — marks cytotoxic GZMB⁺ Tph subcluster in dengue scRNA-seq (sources: 1)
- TOX2 — marks IL-21⁺ helper Tph subcluster; Tfh-associated TF on CXCR5⁻ cells (sources: 1)
Enzymes
- AID — activation-induced cytidine deaminase; initiates SHM and CSR; AID⁺ B cells preserved in COVID-19 despite GC loss; EF SHM at GC-comparable rates (William2002) (sources: 2)
Cytokines
- TNF-alpha — pleiotropic pro-inflammatory cytokine; aberrant accumulation in COVID-19 LNs blocks GC-TFH differentiation; dose-dependent GC role; murine TNF-α blockade rescues GCs (sources: 1)
- IL-21 — key EF differentiation cytokine; produced by Tph and Tfh; robustly induces CD11c in ABC differentiation; blocking reduces PB output ~60% in dengue (sources: 3)
Concepts (8)
- Extrafollicular Response — FIRST DENGUE EVIDENCE: Tph→IL-21→memory B cell→PB axis; CD21⁻CD11c⁺ EF B cells; tissue-level GC suppression + EF dominance (Kaneko2020): antigen-driven expansion, FDC-preserved lymphocyte block, naive/transitional consumption; 47%/87% PB severity association; plasmablast–neutralization disconnect; isotype-fate segregation (IgG→PB, IgM→GC); LANDMARK murine proof of EF SHM (William2002); alternative lineage challenges EF pre-PB model — context-dependent; ABC differentiation programme (TLR7/9+IFN-γ/IL-21) as comparative backbone (sources: 20)
- Germinal Center — canonical differentiation; SM vs DN2 epigenetic bifurcation; tissue-level GC loss in fatal COVID-19 (Kaneko2020): Bcl-6⁺ GC B cells and GC-TFH absent, TNF-α implicated; concurrent GC activity in dengue (CXCL13↑); GCs not required for SHM (William2002); alternative lineage SHM consistent with post-GC origin; ABCs partly GC-experienced + T-bet⁺ B cells promote GC formation (sources: 19)
- Memory B Cell — Tph preferentially drive memory (not naive) B cell→PB in dengue; DENV-specific qualitative reprogramming in 2°; convergent CDR3s from affinity-matured memory B cells; PBs non-representative subset of MBC pool; OAS = strongest functional evidence of memory origin; isotype-fate segregation (IgM→GC, IgG→PB); MBC1 = quiescent alternative lineage memory (Sutton2021) (sources: 17)
- Somatic Hypermutation — LANDMARK: EF SHM at GC-comparable rates (William2002); AID⁺ B cells preserved despite GC loss (Kaneko2020); >50% germline VH in COVID-19 ASCs; FIRST DENGUE BCR DATA: 4.4–6.9% V mutation in convergent CDR3-bearing cells; paradoxically low in acute dengue; HIGH SHM (18.1 VH) in sorted 2° PBs = memory origin; significant SHM in alternative lineage clusters; ABCs (incl. IgD⁺ fraction) carry SHM (sources: 19)
- Class Switch Recombination — EF CSR-competence confirmed; AID preserved outside GCs (Kaneko2020); class-switched memory B cells are Tph responders in dengue; IgG-dominant PBs vs IgM-enriched DENV-binding MBCs; ABCs predominantly switched (IgG/IgA) with unswitched IgD⁺ fraction (sources: 16)
- Original Antigenic Sin — memory recall bias toward prior serotype; 2/4 patients preferentially neutralise DENV1 over infecting DENV2; OAS at mAb level; lower SHM in secondary (GodoyLozano2016); convergent CDR3s more prevalent in secondary (Parameswaran2013); selective E-specific IgG memory recruitment (Appanna2016); Tph→MBC→PB recall engine (Ansari2025); contested — Brazilian cohort shows infecting-serotype dominance (GarciaBates2013) (sources: 7)
- Antibody-Dependent Enhancement — 45/53 dengue PB mAbs enhance infection regardless of neutralisation potency; ADE-competent IgG from memory recall; future-exposure risk; plasmablast–PRNT₅₀ disconnect (GarciaBates2013); neutralizing Ab paradox across dengue and COVID-19 (Ansari2025, Woodruff2020); unmeasured BMPC compartment (Bhattacharya2016) (sources: 5)
- Dengue Severity Classification — clinical-context anchor for the severity axis; WHO-1997 (DF/DHF/DSS = plasma-leakage syndrome) vs WHO-2009 (Dengue±Warning Signs / Severe Dengue); revised scheme more sensitive for triage (92.1% vs 39.0%) but dissolves the pathogenic entity; schemes agree only κ=0.25 → severity findings are scheme-dependent (Narvaez2011, between-scheme); and “WHO-2009” is not one operational definition — only 2 of 16 signs have a consensus definition (Morra2018, within-scheme) → the two heterogeneities stack (sources: 2)
Methods (22)
- Spectral Flow Cytometry — 24-marker Cytek Aurora panels; UMAP; Woodruff2020 Table 1 standardised B cell definitions (sources: 1)
- CITE-seq — multi-modal scRNA-seq + surface protein (ADT); CD21⁻CD27⁻ captures only 44.7% of transcriptomic atBCs; CD11c best single marker (sources: 1)
- Multi-color Immunofluorescence — tissue-based imaging; TissueFAXS/TissueQuest/StrataQuest; 5–7-color multispectral; cell-to-cell contact quantification; FFPE tissue analysis (sources: 1)
- Conventional Flow Cytometry — multi-color panels; Wrammert2012 (5-color) + GarciaBates2013 + Appanna2016 + Ansari2025 + Priyamvada2016 + Kaneko2020 (13-color) panels; CITE-seq gating validation (sources: 15)
- Bm Classification — IgD/CD38 Bm1–Bm5 developmental staging framework (sources: 2)
- FACS Sorting — multi-population sort for multi-omic profiling; antigen-specific live virus sorting; RBD dual-fluorophore probes (Kaneko2020); activated CD4⁺ T cell sorting for scRNA-seq; tetramer-based sorting for Smart-seq2 (sources: 10)
- BCR Sequencing — Sanger, NGS, 10x Chromium scV(D)J, 454 pyrosequencing, microdissection+Vκ PCR, Smart-seq2 full-length BCR; germline-dominant repertoire in COVID-19 EF ASCs; first dengue BCR data (Parameswaran2013); PB/MBC clonal overlap analysis; ImmunediveRsity pipeline + Monte Carlo deconvolution; EF genealogical trees (William2002) (sources: 10)
- RNA Sequencing — 5,090 DEGs; PageRank TF network; EGR4 apex; ATF3 DN2-specific (sources: 2)
- ATAC-seq — comprehensive multi-subset comparison; T-BET/AP-1/EGR motifs in DN2 (sources: 2)
- RRBS — reduced-representation bisulfite sequencing; progressive hypomethylation hierarchy (sources: 1)
- ELISpot — antigen-specific ASC quantification; DENV-specific IgG quantification; FluoroSpot for IL-21/IFN-γ in dengue (sources: 7)
- In Vitro B Cell Stimulation — TLR7/IFN-γ/IL-21 EF differentiation; T-B coculture (sources: 3)
- Phospho-Flow Cytometry — pERK/pMAPKp38 TLR7 readout; DN2/aNAV hyper-responsiveness (sources: 1)
- Serum Proteomics — LC-MS/MS identification of serum antibodies from NGS databases (sources: 1)
- Activation-Induced Marker Assay — CD25⁺OX40⁺ AIM assay for DENV-specific T cell responses (sources: 1)
- Single-Cell RNA Sequencing — 10x Genomics scRNA-seq + scTCR-seq; Tph subcluster identification in dengue; Smart-seq2 + 10x Chromium + CITE-seq for B cell lineage definition (sources: 2)
- T-B Coculture Assay — Tph-driven memory B cell→PB differentiation; IL-21 blocking (sources: 1)
- FRNT — focus reduction neutralization test; neutralizing titers not different by dengue severity; OAS demonstrated at mAb FRNT₅₀ level (sources: 2)
- PRNT — plaque reduction neutralization test; PRNT₅₀ not correlated with plasmablast frequency in dengue (sources: 1)
- Immunohistochemistry — tissue-based protein localisation; EF B cell localisation at T zone–red pulp border (sources: 1)
- Compensation and FMO Controls — spillover matrix vs. FMO controls distinction; curator’s 11-color DN2 panel worked example: FMO-anchored IgD/CD27 cutoffs reveal old DN gate undercounted by ~4.5x (1.99%→8.90% of B cells) (sources: 2)
- DN2 Panel - Staining, Compensation, and Gating Protocol — end-to-end operational SOP for the curator’s 11-color DN2 panel: whole-blood prep → unstained/single-stain-bead/FMO controls → FlowJo compensation → FMO-anchored gating, with worked examples, analogies, and an honest limitations section (sources: 2)
Analyses (7)
- B Cell Panel Variant 1 — intracellular-capable B-cell panels for the 3-laser/14-channel instrument; recommended single-tube 13-color workhorse (Panel 4) confirming DN2/ABC (adds T-bet) + DN2:DN1 ratio (adds CXCR5) + plasmablast/EF-effector output; 3-tube suite (Panels 1–3) for higher cell yield; supersedes the surface-only DN2 Gating Strategy panel
- DN2 Gating Strategy — council-reviewed 11-color gating strategy for DN/DN2-phenotype isolation in dengue PBMCs; Ansari2025-comparable; Sanz2025 IgD-audit compliant
- Research Plan - DN B Cell Expansion in Dengue — wet-lab protocol (Rev 4): flow cytometry panel, cohort design (DF/DHF/HC), DN1-like/DN2-phenotype/DN3-like surrogate subdivision, sample size estimates
- Thesis Objectives and Grant Pitch — strategic layer for the pilot: central thesis (one low-fidelity antibody, two faces), falsifiable objectives (cells→ANA bridge as primary), statistical-honesty framing, confounder pre-emption (age/sex first-order for ABCs), antibody layer (ANA + FRNT×4 + IgG/IgM), severity-scheme decision, pilot→grant trajectory; complements the Research Plan
- Notable Findings — running log of striking cross-cutting observations (16 entries)
- Curator Highlights — aggregated
==highlights==and “ from wiki pages (2 highlights) - External Citation Audit — catalog of 54 external papers cited inline across ~25 wiki pages; DOIs, backlinks, verification status